Dr. Asma Patel: What are the biggest barriers to rare disease drug development?

In 2023, February 28th marked Rare Disease Day. Eurpoean Pharma Manufacturing and Drug Discovery World asked Dr. Asma Patel, vice president of integrated services for early development at Quotient Sciences, what barriers remain in orphan rare disease drug development and the strategies that can bring the much-needed drugs to market faster.

In the article, Dr. Asma Patel shares that there are four main barriers impacting the development of orphan programs: (1) increasingly constrained R&D budgets, (2) challenging product development, which may need to be specialised on a per patient basis, (3) problematic clinical recruitment in rare patient populations and (4) regulatory hurdles in striving for fast track and accelerated approval.

You can read more of Dr. Asma Patel's insightful article or orphan rare disease drug development by clicking either of the links below.

Continue Reading on European Pharma Manufacturing   or  Continue Reading on Drug Discovery World